The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial

BMC Psychiatry

Haya Ascher-Svanum³  Tiago R Marques²  Paul Succop¹  Virginia Stauffer³  Bruce J Kinon³  Joseph A Johnston³  Lei Chen³ 

[1] University of Cincinnati, Cincinnati, OH, USA;Department of Psychosis Studies, Institute of Psychiatry, King’s College London, London, UK;Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA

关键词: Schizophrenia;    Trajectory interplay;    Negative symptoms;    Positive symptoms;   

Others  :  1123876
DOI  :  10.1186/1471-244X-13-320

 received in 2012-12-17, accepted in 2013-11-19,  发布年份 2013

【 摘 要 】

Background

Schizophrenia is a highly heterogeneous disorder with positive and negative symptoms being characteristic manifestations of the disease. While these two symptom domains are usually construed as distinct and orthogonal, little is known about the longitudinal pattern of negative symptoms and their linkage with the positive symptoms. This study assessed the temporal interplay between these two symptom domains and evaluated whether the improvements in these symptoms were inversely correlated or independent with each other.

Methods

This post hoc analysis used data from a multicenter, randomized, open-label, 1-year pragmatic trial of patients with schizophrenia spectrum disorder who were treated with first- and second-generation antipsychotics in the usual clinical settings. Data from all treatment groups were pooled resulting in 399 patients with complete data on both the negative and positive subscale scores from the Positive and Negative Syndrome Scale (PANSS). Individual-based growth mixture modeling combined with interplay matrix was used to identify the latent trajectory patterns in terms of both the negative and positive symptoms. Pearson correlation coefficients were calculated to examine the relationship between the changes of these two symptom domains within each combined trajectory pattern.

Results

We identified four distinct negative symptom trajectories and three positive symptom trajectories. The trajectory matrix formed 11 combined trajectory patterns, which evidenced that negative and positive symptom trajectories moved generally in parallel. Correlation coefficients for changes in negative and positive symptom subscale scores were positive and statistically significant (P < 0.05). Overall, the combined trajectories indicated three major distinct patterns: 1) dramatic and sustained early improvement in both negative and positive symptoms (n = 70, 18%), 2) mild and sustained improvement in negative and positive symptoms (n = 237, 59%), and 3) no improvement in either negative or positive symptoms (n = 82, 21%).

Conclusions

This study of symptom trajectories over 1 year shows that changes in negative and positive symptoms were neither inversely nor independently related with each other. The positive association between these two symptom domains supports the notion that different symptom domains in schizophrenia may depend on each other through a unified upstream pathological disease process.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Tsuang MT, Lyons MJ, Faraone SV: Heterogeneity of schizophrenia. Conceptual models and analytic strategies. Br J Psychiatry 1990, 156:17-26.
• [2]McGrath J: Dissecting the heterogeneity of schizophrenia outcomes. Schizophr Bull 2008, 34(2):247-248.
• [3]Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J, Kinon BJ: The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med 2011, 41(06):1291-1300.
• [4]Levine SZ, Leucht S: Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry 2010, 68(1):86-92.
• [5]Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H: Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res 2012, 137(1–3):141-146.
• [6]Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H: Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol 2010, 30(4):446-449.
• [7]Levine SZ, Rabinowitz J: Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull 2010, 36(3):624-632.
• [8]Levine SZ, Lurie I, Kohn R, Levav I: Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr Res 2011, 126(1–3):184-191.
• [9]First MB: Diagnostic and statistical manual of mental disorders 4th Ed. (DSM-IV-TR™, 2000), 4 edn. American Psychiatric Association: Washington, DC; 2000.
• [10]Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148(10):1301-1308.
• [11]Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998, 155(6):751-760.
• [12]Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, et al.: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001, 58(10):965-972.
• [13]Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR: The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32(2):214-219.
• [14]Levine BG, Stone JE, Kohlmeyer A: Fast analysis of molecular dynamics trajectories with graphics processing units-radial distribution function Histogramming. J Comput Phys 2011, 230(9):3556-3569.
• [15]Lyne J, O’Donoghue B, Owens E, Renwick L, Madigan K, Kinsella A, Clarke M, Turner N, O’Callaghan E: Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophr Res 2012, 135(1–3):128-133.
• [16]Addington J, Addington D: Positive and negative symptoms of schizophrenia. Their course and relationship over time. Schizophr Res 1991, 5(1):51-59.
• [17]Andreasen NC, Olsen SA, Dennert JW, Smith MR: Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am J Psychiatry 1982, 139(3):297-302.
• [18]Carpenter WT Jr, Bartko JJ, Carpenter CL, Strauss JS: Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia. Arch Gen Psychiatry 1976, 33(4):508-516.
• [19]Andreasen NC: Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982, 39(7):784-788.
• [20]Cuesta MJ, Peralta V: Current psychopathological issues in psychosis: towards a phenome-wide scanning approach. Schizophr Bull 2008, 34(4):587-590.
• [21]Goghari VM, Sponheim SR, MacDonald AW 3rd: The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev 2010, 34(3):468-486.
• [22]Guelfi GP, Faustman WO, Csernansky JG: Independence of positive and negative symptoms in a population of schizophrenic patients. J Nerv Ment Dis 1989, 177(5):285-290.
• [23]Javitt DC: Twenty-five years of glutamate in schizophrenia: are we there yet? Schizophr Bull 2012, 38(5):911-913.
• [24]Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R: Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006, 9(2):77-89.
• [25]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
• [26]Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988, 23(1):99-110.
• [27]Santor DA, Ascher-Svanum H, Lindenmayer JP, Obenchain RL: Item response analysis of the positive and negative syndrome scale. BMC Psychiatry 2007, 7:66. BioMed Central Full Text
• [28]Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD: Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008, 28(2 Suppl 1):S20-S28.
• [29]Kane JM, Assuncao-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT: The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophr Res 2008, 105(1–3):208-215.
• [30]Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A: Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70(6):829-836.
• [31]Muthen B, Muthen L: Mplus - Statistical analysis with latent variables - user’s guide. 5th edition. Muthen and Muthen: Los Angeles; 2007.
• [32]Muthen B: Latent variable mixture modeling. In New developments and techniques in structural equation modeling. Edited by Marcoulides GA, Schumacker RE. Mahwah, NJ: Lawrence Erlbaum Associates; 2001:1-33.
• [33]Bauer DJ, Curran PJ: Distributional assumptions of growth mixture models: implications for overextraction of latent trajectory classes. Psychol Methods 2003, 8(3):338-363.
• [34]Pearson WH: Estimation of a correlation coefficient from an uncertainty measure. Psychometrika 1966, 31(3):421-433.
• [35]Gueorguieva R, Mallinckrodt C, Krystal JH: Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry 2011, 68(12):1227-1237.
• [36]Marques TR, Arenovich T, Agid O, Sajeev G, Muthen B, Chen L, Kinon BJ, Kapur S: The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med 2011, 41(7):1481-1488.
• [37]Stauffer V, Case M, Kollack-Walker S, Ascher-Svanum H, Ball T, Kapur S, Kinon BJ: Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res 2011, 130(1–3):11-19.
• [38]Crow TJ: The two-syndrome concept: origins and current status. Schizophr Bull 1985, 11(3):471-486.
• [39]Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 2009, 35(3):549-562.
• [40]Carpenter WT Jr, Heinrichs DW, Wagman AM: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988, 145(5):578-583.
• [41]Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997, 154(4):466-474.
• [42]Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR: Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr Res 2012, 134(2–3):195-201.
• [43]Kinon BJ, Kane JM, Chakos M, Munne R: Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993, 29(3):365-369.
• [44]Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP: Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Pref Adher 2011, 5:547-554.
• [45]Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J: Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res 2009, 169(2):97-100.
• [46]Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996, 124(1–2):159-167.
• [47]Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996, 14(2):111-123.
• [48]Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al.: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007, 13(9):1102-1107.
• [49]Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT: The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 2004, 19(1):21-26.